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Integrated transcriptomic and high-resolution whole
genome methylation analysis in a myeloid leukemia
cell line defines genes that respond to clinically relevant
DNA methyltransferase inhibitors.an attempt to identify the gene targets of hypomethylatingNucleotide sequence serves as the essential text of the
genetic ‘book’ known as the human genome, but this book
also comes with ‘reading instructions’, ‘bookmarks’ and
‘highlighted passages’ in the form of epigenetic patterns.
Not surprisingly, the initiation and progression of cancer
are governed not only by the accumulation of genetic
lesions in the text itself but also by perturbations
in the epigenome. Indeed, epigenetic alterations that
dysregulate the ability of cancer cells to utilize genomic
information are increasingly being appreciated as an im-
portant contributing factor in the development of differ-
ent malignancies [1].Epigenetic therapies for malignancies
Unlike genetic lesions, epigenetic patterns are relatively
fluid and might be correctable by therapeutic perturba-
tions. Such malleability has made epigenetic therapies
an attractive alternative to cytotoxic chemotherapies.
Rather than trying to destroy rapidly dividing cells in-
stantly, epigenetic therapies aim to reprogram cancer cells
by attenuating cancer-promoting transcriptional networks
[1]. These therapies, specifically the DNA hypomethylat-
ing agents 5-azacitidine (Aza) and 5-aza-2′-deoxycytidine
(decitabine, Dac), have been used increasingly for the
treatment of patients with myelodysplastic syndrome
(MDS) and acute myeloid leukemia (AML) [2]. Despite* Correspondence: leviner@mskcc.org
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1.0/) applies to the data made available in this artthe successful use of both Aza and Dac in the clinic,
the molecular mechanisms behind their efficacy re-
quires additional investigation. In this issue of Genome
Biology, Lund et al. [3] employ a sophisticated method-
ology, which they term WIMSi, to sift through high-
resolution DNA methylomic and transcriptomic data in
therapies [3].
Myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML) are malignant disorders of hematopoietic
progenitor cells that lead to defective hematopoiesis. MDS
is characterized by cytopenia (a reduction in the number
of blood cells); AML, on the other hand, is typified by
leukocytosis, which primarily results from the expansion
of immature myeloid blasts. Both types of malignancies
are most commonly diagnosed later in life (median age
at AML diagnosis is 68 years). An intense interest in
demethylating therapies for AML and MDS has been
fueled by the presence of hallmark focal DNA hyperme-
thylation that distinguishes leukemic blasts from normal
hematopoietic progenitors, and by the high frequency of
somatic mutations in genes that regulate the methyla-
tion of genomic DNA, including IDH1/2, TET2, and
DNMT3A [1,2,4,5], in myeloid malignancies.
Under investigation: mechanism of action of
hypomethylating drugs
The classical view of the establishment and maintenance
of site-specific DNA methylation posits that methyl groups
are introduced at CpG palindromic sites by de novo DNA
methyltransferases (DNMTs; DNMT3A and DNMT3B)
over the course of cellular differentiation, starting in em-
bryogenesis. After each round of replication, the methyla-
tion pattern can be copied from the (methylated) parent
strand to the (unmethylated) daughter strand by the main-
tenance methyltransferase DNMT1 because of its pref-
erence for hemimethylated DNA. The TET family of
enzymes can mediate active DNA demethylation, al-
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methylation also decreases passively in the absence of
re-methylation [1]. Passive demethylation is thought to
underlie the mechanism of action of DNMT inhibitors.
The nucleoside analogs Aza and Dac, and their metabo-
lites, act as DNMT suicide substrates upon incorporation
into replicating DNA. Additionally, exposure to higher
doses of these agents results in bulky adduct formation
and DNA damage [2,6].
Cancer-associated focal DNA hypermethylation, espe-
cially in the promoter regions of key effector genes, is
believed to be responsible for silencing critical tumor
suppressors, such as pro-apoptotic genes and regulators
of the cell cycle and differentiation commitment [1,6,7].
Treatment with DNMT inhibitors induces early loss of
DNA methylation, even at low drug doses [6,8], but pub-
lished studies report discordant effects of hypomethylating
agents on gene expression [6-8]. Some investigators ob-
served widespread reactivation of silenced tumor suppres-
sor genes in response to DNMT inhibitors. Others failed
to detect any relationship between DNA hypomethylation
and gene expression, despite consistent robust correlation
between DNA methylation and gene repression in un-
treated primary cultured cells and cell lines [6,7,9]. The
very short extent of treatment (most studies chose 48 to
72 hour timepoints) [6,8] may not be sufficient to induce
robust changes in gene expression despite early widespread
hypomethylation. In addition, the accumulation of DNA
methylation during gene silencing precedes the deposition
of repressive histone marks and chromatin compaction. It
is conceivable that the same would hold true during gene
reactivation and would require days rather than hours.
As an alternative hypothesis to explain why there was no
correlation between gene expression and DNA methyla-
tion changes, Lund et al. [3] reasoned that the limited
resolution and skewed representation of genomic features
inherent in a previous generation of experimental methods
were to blame. To zero in on a list of candidate genes
regulated exclusively by DNA methylation, Lund et al.
[3] investigated a combined dataset of high-resolution
whole-genome bisulfite sequencing (WGBS) data and
gene expression profiles by RNA-seq in an AML cell line
treated with Aza. Although higher than that used in previ-
ously published studies, a low dose of Aza (0.5 μM) was
chosen to minimize changes in cell proliferation and DNA
damage. DNA damage and changes in proliferation rates
induced by high-dose Aza may obscure the impact of
DNA demethylation on gene expression. To avoid this the
authors chose a significantly lower dose that did not affect
proliferation and did not induce DNA damage.
The study focused on the OCI/AML-3 leukemic cell
line, which is known to carry mutations in the NPM1 and
DNMT3A genes. The nucleophosmin gene NPM1 is one
of the most frequently mutated genes in AML. Mutationsin NPM1 most often disrupt its nuclear localization signal
and are associated with favorable prognosis [4,5]. Even
though NPM1 is not directly involved in the regulation of
DNA methylation, mutated NPM1 defines a distinct epi-
genetic cluster identified by the DNA methylation profil-
ing of 344 AML patients [9]. DNMT3A is another gene
that is frequently mutated in AML. In contrast to NPM1
mutations, DNMT3A mutations predict poor survival
rates [1,5]. The presence of two mutations with opposite
prognostic effects challenges unequivocal risk stratifica-
tion. Despite the frequent occurrence of mutations in both
NPM1 and DNMT3A in AML, the co-occurrence of
mutations in both of these genes in the absence of FLT3
internal tandem duplications (FLT3-ITD) is relatively
uncommon [4]. Consequently, the OCI/AML-3 cell line
does not reflect the genotypic context most commonly
observed in AML patients whose leukemia cells carry
these mutant disease alleles.
DNMT3A is directly involved in the establishment and
maintenance of DNA methylation patterns, and DNMT3A
mutant AML patient-derived samples show a small but
significant decrease in mean methylation relative to non-
mutated samples [10]. Despite having solid adverse prog-
nostic implications, the predictive value of DNMT3A
mutations with respect to the response to hypomethy-
lating agents has not been conclusively established.
Overall, four small-scale clinical trials that investigated
the relationship between DNMT3A mutations and response
to hypomethylating agents showed a trend towards pro-
longed progression-free survival (PFS) and higher complete
remission (CR) rate in those carrying the mutation [2].
The authors’ general characterization of the DNA-
methylation landscape by WGBS confirmed previous
findings [6,7,9]: methylation is enhanced in the bodies
(transcribed portions) of highly expressed genes, but
there are low methylation levels in promoters and an
almost complete loss of methylation just downstream
of transcriptional start sites. Treatment of OCI/AML-3
cells with Aza resulted in general, genome-wide hypo-
methylation; genomic features with the highest levels of
methylation pre-treatment were affected to the greatest
extent. Consistent with most previously published stud-
ies, there was no obvious correlation between DNA hy-
pomethylation at gene promoters or CpG islands and
expression of the corresponding gene. The authors then
used WIMSi (Washington University Interpolated Methy-
lation Signatures), a more sophisticated computational ap-
proach, to tease out subtle co-regulation between DNA
methylation and gene expression [3].
WIMSi analysis identifies genes directly regulated
by DNA methylation
WIMSi analysis relies on the identification of gene clusters
that share similar DNA methylation profiles by shape-
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and after treatment with Aza to identify specific genes or
loci of interest. This approach yielded a list of 246 dere-
pressed genes that have functions in cell death and sur-
vival or in cell movement and proliferation, all presumably
regulated directly by DNA methylation. Cross-validation
with other published datasets showed that WIMSi genes
were enriched among genes whose expression was down-
regulated in AML compared to normal hematopoietic
stem and progenitor cells (HSPCs). Many WIMSi genes
were also found as upregulated in a previous study investi-
gating the impact of DNMT inhibitors on methylation
and gene expression in primary AML samples that failed
to detect a relationship between DNA hypomethylation
and gene expression by more general methods [6]. Over-
all, the study by Lund et al. [3] demonstrates the feasibility
of using high-resolution WGBS and RNA-seq, when com-
bined with sophisticated computational methods, to un-
cover relationships between DNA methylation and gene
expression.
As with any novel methodology, this study raises many
questions for subsequent investigation. First, the question
of whether other epigenetic marks are involved in early
regulation of gene expression is the most important and
the most informative. Are DNA methylation and histone
modifications co-regulated, or does one direct the other?
What is the timing of the chromatin reorganization that is
necessary to allow gene de-repression, and what is the op-
timal time point at which to measure it? Would histone
modifications be more directly related to changes in gene
expression than changes in DNA methylation? Compre-
hensive epigenetic profiling that integrates analysis of the
DNA methylome, the epigenome and the transcriptome
will further our understanding of the mechanisms behind
the efficacy of hypomethylating therapies. Such studies
will be welcomed with great enthusiasm in the field of
clinical cancer epigenetics. Second, what are the implica-
tions of the apparent reprogramming of OCI/AML-3 cells
into a state more similar to HSPCs after Aza exposure?
Are the effects on self-renewal genes distinct from those
on differentiation and lineage-commitment genes? How
similar are the reprogrammed profiles to those of more
mature populations? Detailed studies involving additional
leukemic and normal samples will be needed to shed light
on the complex processes that guide epigenetic repro-
gramming. Finally, how generalizable are these findings,
given the specific genetic make-up of the OCI/AML-3
cells and the uncertain impact of DNMT3A mutational
status on predicting response to hypomethylating agents?
Extension of these studies to cellular models (cell lines or
primary AML samples) with more relevant and compre-
hensive mutational landscapes will be eagerly awaited.
In the book of life that is the genome, aberrant DNA
hypermethylation that silences tumor suppressor genescan be likened to pages that are stuck together, concealing
important plot twists. Hypomethylating therapies can peel
these pages apart and open the book at the right chapter.
Whether it will be fully readable and able to guide the re-
programming of malignant cells, and what other signals
or epigenetic marks are needed to promote proper gen-
ome reading, are questions that we are just beginning to
answer.
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